KRM Ayurveda Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹485 Cr
- P/E
- 19.29
- ROE
- 29.03%
- PEG
- 0.51
- Price to sales
- 4.77
- Debt to equity
- 0.00
- 52W high / low
- ₹344 / ₹156
- EBITDA margin
- 29.99%
- Net profit margin
- 19.79%
- Promoter holding
- 69.30%
- Sales (last year)
- ₹102 Cr
Incorporated on 3 September 2019, KRM Ayurveda Ltd. is operating a network of hospitals and clinics across multiple cities in India.[1]
Guidance scorecard · Q1 FY27 call
What KRM Ayurveda's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ4 FY26 call
40%+- KRM Ayurveda targets a minimum 50% year-on-year revenue growth over the next few years.
- Growth drivers include adding approximately 1,500 to 2,000 beds over the next three years across India.
- Plans to open around 100 super-specialty clinics within three years, enhancing disease-specific treatments and increasing patient inflow.
- Expansion includes 30 new clinics in the current year and increasing bed capacity from ~235 to 500 beds by year-end.
- Telemedicine expansion with a new 500-seater center to double revenue from products and services.
- Product sales will grow alongside clinic and hospital expansion, supported by e-commerce launches.
2 more points from KRM Ayurveda's call on revenue
Create a free account to keep reading this call
MarginsQ4 FY26 call
Up 2%+See what KRM Ayurveda said on margins — free account, 30 seconds.
CapexQ4 FY26 call
Planned- Planning to add approximately 2,000 beds over the next 3-4 years with a cost around ₹2 lakh per bed.
- Expansion plans include adding 1500 to 2000 beds pan-India and opening about 100 super-specialty clinics over the next three years.
- Expect to increase bed capacity from 235 to 500 beds in FY27, with finalized agreements for additional 100-bed hospital in Gurgaon.
- Building a 500-seater telemedicine center operational in 1 to 1.5 years to support expansion.
- New luxury hospital of 25 beds being developed in Delhi, with scope for expansion.
2 more points from KRM Ayurveda's call on capex
Create a free account to keep reading this call
FundraisingQ4 FY26 call
See what KRM Ayurveda said on fundraising — free account, 30 seconds.
Order bookQ4 FY26 call
Ask what KRM Ayurveda said on the order book →
Full Q4 FY26 analysisRanges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- 1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | KRM AyurvedaThis stock | 40%+ | Up 2%+ | ₹480 Cr | 19.1 |
| 2 | 40%+ | Up 0–2% | ₹212 Cr | 16.1 | |
| 3 | 40%+ | Flat | ₹17,925 Cr | — | |
| 4 | 40%+ | Flat | ₹5,223 Cr | 39.1 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹51,093 Cr | 44.6 |
Sign up free to see every company in the sector ranking and track KRM Ayurveda.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of KRM Ayurveda
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of KRM Ayurveda
Quarterly Results
Quarter-by-quarter operating performance
Financials of KRM Ayurveda
Profit & Loss
Annual income statement trend
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales + | 89 | 67 | 77 | 102 |
| Expenses + | 78 | 60 | 57 | 71 |
| Operating Profit | 11 | 8 | 19 | 30 |
| OPM % | 13% | 11% | 25% | 30% |
| Other Income + | 0 | 0 | 0 | 1 |
| Interest | 1 | 2 | 2 | 3 |
| Depreciation | 1 | 1 | 1 | 1 |
| Profit before tax | 10 | 5 | 16 | 27 |
| Tax % | 25% | 28% | 26% | 25% |
| Net Profit + | 8 | 3 | 12 | 20 |
| EPS in Rs | 5,066.67 | 2,273.33 | 806.67 | 9.46 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
Financials of KRM Ayurveda
Balance Sheet
Capital structure and asset base
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.15 | 0.15 | 0.15 | 21 |
| Reserves | 8 | 12 | 24 | 93 |
| Borrowings + | 20 | 23 | 31 | 0 |
| Other Liabilities + | 11 | 9 | 12 | 8 |
| Total Liabilities | 39 | 44 | 67 | 122 |
| Fixed Assets + | 23 | 23 | 27 | 26 |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 38 |
| Other Assets + | 16 | 21 | 40 | 58 |
| Total Assets | 39 | 44 | 67 | 122 |
Financials of KRM Ayurveda
Cash Flows
Operating, investing and financing cash movement
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from Operating Activity + | 4 | -1 | -0 | 1 |
| Cash from Investing Activity + | -23 | -0 | -4 | -30 |
| Cash from Financing Activity + | 19 | 1 | 6 | 37 |
| Net Cash Flow | 0 | 0 | 2 | 7 |
| Free Cash Flow | -20 | -1 | -5 | 0 |
| CFO/OP | 36% | 33% | 14% | 29% |
Financials of KRM Ayurveda
Ratios
Working capital efficiency and return ratios
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 32 | 30 | 58 | 82 |
| Inventory Days | 13 | 53 | 296 | 225 |
| Days Payable | 100 | 141 | 205 | 80 |
| Cash Conversion Cycle | -55 | -58 | 149 | 227 |
| Working Capital Days | 9 | 48 | 64 | 280 |
| ROCE % | 22% | 42% | 35% |
Continue your research
What KRM Ayurveda's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Neuland Laboratories (Q2 FY27)
Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q
- Hikal (Q2 FY27)
Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest
- Kopran (Q2 FY27)
9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
- Emcure Pharma (Q2 FY27)
Q2FY27 Revenue from Operations: INR 28,205 Mn, up 24.3% YoY (Page 9). Key investor presentation takeaways from Emcure Pharmaceuticals Ltd's Q2 FY27 investor pre